Skip to content

Clinical observation of Auricularia auricula-judae in preventing postoperative liver metastasis in patients with stage II-III colorectal cancer

Clinical observation of Auricularia auricula-judae in preventing postoperative liver metastasis in patients with stage II-III colorectal cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075003
Enrollment
Unknown
Registered
2023-08-22
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Auricularia auricula-judae diet group:On the basis of normal diet, the total amount of dried Auricularia auricula-judae is 30g per week, which can be divided into 3-4 days to eat, dry Auricularia auri
Auricularia auricula-judae free diet group:Normal diet, diet does not contain black fungus.

Sponsors

Hebei General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? =18 years old and =75 years old; ? Postoperative pathology confirmed stage II-III colorectal cancer; ?ECOG score 0-2; ? Expected survival time >6 months; ? no bad living and eating habits; ?No history of malignant tumors other than colorectal cancer; ? Sign written informed consent prior to the implementation of any trial related procedures.

Exclusion criteria

Exclusion criteria: ? Pregnant or lactating women; ? Patients with allergy or intolerance to Auricularia auricula-judae; ? Patients with bad living habits such as alcoholism and long-term smoking; ? Patients with severe cardiovascular and cerebrovascular diseases or liver and kidney dysfunction who cannot tolerate chemotherapy; ? Patients with acute and chronic infection; ? Patients who are also participating in other clinical trials; ? Patients with cognitive impairment, poor compliance, and difficulty in cooperating with the completion of the study.

Design outcomes

Primary

MeasureTime frame
Liver metastasis recurrence rate;

Secondary

MeasureTime frame
Tumor markers CEA and CA199;Cytokines;Intestinal flora;living quality;mental state;

Countries

China

Contacts

Public ContactJia YiTtao

Hebei General Hospital

jiayitao99@163.com+86 135 0311 3385

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026